Can a gene make prostate cancer cells soak up radiation?

NCT ID NCT00788307

Terminated ⭐️ CURE ⭐️ Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 1 trial tests a gene therapy that helps prostate cancer cells absorb more radioactive iodine, potentially killing them while sparing healthy tissue. The study enrolls men whose prostate cancer returned after prior radiation therapy. Researchers aim to find the safest dose and evaluate side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a gene therapy (Ad5CMV-NIS) plus radioactive iodine (I-131) and liothyronine sodium
What this could lead to: If successful, this approach could offer a new treatment option for men with prostate cancer that returns after radiation therapy.
What could go wrong: This is an early phase 1 trial with only 8 participants, focused on safety and dosing. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.